Arcturus Therapeutics is trading 5.31% lower at $10.16; broader market weakness may be contributing, but no fresh company-specific announcement explaining the October 23 move surfaced.
- The S&P 500 is down 0.52% and the Dow is down 1.07%, making global-market pressure a plausible factor, not an established sole cause.
- A September 23 clinical update and an October 23 report of a Zacks upgrade do not clearly explain the decline.